Summary
Abstract
Dexrazoxane (Cardioxane®, Zinecard®), a cyclic derivative of edetic acid, is a site-specific cardioprotective agent that effectively protects against anthracycline-induced cardiac toxicity. Dexrazoxane is approved in the US and some European countries for cardioprotection in women with advanced and/or metastatic breast cancer receiving doxorubicin; in other countries dexrazoxane is approved for use in a wider range of patients with advanced cancer receiving anthracyclines.
As shown in clinical trials, intravenous dexrazoxane significantly reduces the incidence of anthracycline-induced congestive heart failure (CHF) and adverse cardiac events in women with advanced breast cancer or adults with soft tissue sarcomas or small-cell lung cancer, regardless of whether the drug is given before the first dose of anthracycline or the administration is delayed until cumulative doxorubicin dose is ≥300 mg/m2. The drug also appears to offer cardioprotection irrespective of pre-existing cardiac risk factors. Importantly, the antitumour efficacy of anthracyclines is unlikely to be altered by dexrazoxane use, although the drug has not been shown to improve progression-free and overall patient survival. At present, the cardioprotective efficacy of dexrazoxane in patients with childhood malignancies is supported by limited data. The drug is generally well tolerated and has a tolerability profile similar to that of placebo in cancer patients undergoing anthracycline-based chemotherapy, with the exception of a higher incidence of severe leukopenia (78% vs 68%; p < 0.01). Dexrazoxane is the only cardioprotective agent with proven efficacy in cancer patients receiving anthracycline chemotherapy and is a valuable option for the prevention of cardiotoxicity in this patient population
Pharmacological Properties
Dexrazoxane provides cardiac protection from anthracyclines primarily through the metal-chelating activity of its intracellular hydrolysis products in the myocardium. This activity involves chelation of free iron and iron bound in anthracycline complexes, thereby preventing the formation of cardiotoxic reactive oxygen radicals.
In animals treated with cardiotoxic doses of doxorubicin or epirubicin, the incidence of cardiac lesions was significantly reduced and the survival rate significantly increased compared with no dexrazoxane treatment. In animal models, dexrazoxane was more effective when administered immediately prior to, or simultaneously with, rather than after, the anthracycline. In addition, administration of dexrazoxane before the first cardiotoxic dose of doxorubicin was significantly more cardioprotective than delaying the dexrazoxane administration until the sixth doxorubicin dose.
The Pharmacokinetics of intravenous dexrazoxane appear to follow first-order elimination kinetics in a two-compartment model. The absorption kinetics of dexrazoxane are linear within a 6–900 mg/m2 dose range. Tissue distribution of dexrazoxane is rapid, reaching equilibrium within 2–4 hours, with the highest concentrations of the parent drug and its final hydrolysis product being found in the liver and kidneys. Plasma protein binding is minimal. Dexrazoxane is enzymatically hydrolysed to its more active open-ring forms in the liver, kidney, heart, erythrocytes and leukocytes. Elimination is predominantly renal in the unchanged form. Distribution and elimination appear to be significantly greater in children than in adults.
The administration of dexrazoxane at recommended doses 15–30 minutes prior to doxorubicin or epirubicin does not significantly alter the pharmacokinetic properties of either drug.
Therapeutic Efficacy
Dexrazoxane demonstrated significant cardioprotection in women with advanced breast cancer receiving anthracycline chemotherapy. The incidence of anthracycline-induced cardiac events was significantly lower with (0–15%), than without (16–50%), dexrazoxane in all phase III trials. In three of six trials, the incidence of CHF was also significantly lower with (0–3%), than without (8–27%), dexrazoxane in both anthracycline-naive and -experienced patients.
In adults with small-cell lung carcinoma receiving doxorubicin and in those with soft tissue sarcomas (combined analysis of results in breast cancer patients) treated with high-dose epirubicin, dexrazoxane significantly reduced the incidence of anthracycline-induced cardiac events (including CHF in the latter patient group). Dexrazoxane provided effective short- and medium-term cardioprotection in patients (aged ≤24 years) who received anthracycline-based chemotherapy for childhood malignancies, including acute lymphoblastic leukaemia and various types of sarcoma; no long-term data are currently available.
According to two meta-analyses, dexrazoxane significantly reduces the relative risk of anthracycline-induced cardiotoxicity in cancer patients by 72–76% compared with no treatment and does not increase the relative risk of chemotherapy failure or decrease patient survival.
Tolerability
Dexrazoxane is a well tolerated drug with a tolerability profile similar to that of placebo in adult cancer patients receiving anthracycline-based chemotherapy, the difference being a significantly higher incidence of severe leukopenia with dexrazoxane. Limited data in children with malignancies receiving anthracyclines indicate relatively good tolerance of dexrazoxane in this patient population. In addition, dexrazoxane appears equally well tolerated when administered with doxorubicin at either 10: 1 or 20: 1 dosage ratios.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs 1999 Mar; 57(3): 293–308
Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000 Apr; 22(4): 263–302
Picci P, Ferrari S, Bacci G, et al. Treatment recommendations for osteosarcoma and adult soft tissue sarcomas. Drugs 1994; 47(1): 82–92
Wiseman LR, Spencer CM. Dexrazoxane: a review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998 Sep; 56(3): 385–403
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003 Jun 1; 97(11): 2869–79
Speyer J, Wasserheit C. Strategies for reduction of anthracycline cardiac toxicity. Semin Oncol 1998 Oct; 25(5): 525–37
Blum RH. Clinical status and optimal use of the cardioprotectant dexrazoxane. Oncology 1997 Nov; 11(11): 1669–78
Hoekman K, van der Vijgh WJF, Vermorken JB. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Drugs 1999 Feb; 57(2): 133–55
Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998 Nov; 16(11): 3502–8
Lipschultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991 Mar 21; 324(12): 808–15
Lipschultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996; 14: 326–31
Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991 Sep 25; 266(12): 1672–7
Sugioka KA, Nakano M. Mechanisms of phospholipid peroxidation induced by ferric iron-ADP adriamycin co-ordination complex. Biochem Biophys Res Commun 1982; 713: 333–43
Hasinoff BB, Schnabl KL, Marusak RA, et al. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 2003; 3(2): 89–99
Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 1994 Sep; 28: 1063–72
Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 1998 Aug; 25 (4 Suppl. 10): 10–4
Lewis C. A review of the use of chemoprotectants in cancer chemotherapy. Drug Saf 1994 Sep; 11(3): 153–62
Hasinoff BB, Hellmann K, Herman EH, et al. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5(1): 1–28
Hasinoff BB, Schroeder PE, Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 2003 Sep; 64(3): 670–8
Vogel CL, Gorowski E, Davila E, et al. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Invest New Drugs 1987; 5: 187–98
Zinecard® (dexrazoxane for injection) US prescribing information. Kalamazoo (MI): Pharmacia and Upjohn Company, 2003
Earhart RH, Tutsch KD, Koeller JM, et al. Pharmacokinetics of (+)-l,2-Di(3,5-dioxopiperazin-l-yl)propane intravenous infusions in adult cancer patients. Cancer Res 1982 Dec; 42: 5255–61
Rosing H, Ten Bokkel Huinink WW, Van Gijn R, et al. Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluoruracil-doxorubicin-cyclophosphamide (FDC). Eur J Drug Metab Pharmacokinet Jan–Mar 1999; 24(1): 69–77
Holcenberg JS, Tutsch KD, Earhart RH, et al. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 1986 Jun; 70(6): 703–9
Schroeder PE, Davidson JN, Hasinoff BB.Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab Dispos 2002 Dec; 30(12): 1431–5
Hochster H, Liebes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992; 84: 1725–30
Basser RL, Sobol MM, Duggan G, et al. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 1994 Aug; 12(8): 1659–66
Jakobsen P, Sorensen B, Bastholt L, et al. The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. Cancer Chemother Pharmacol 1994; 35: 45–52
Schroeder PE, Jensen PB, Sehested M, et al. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother Pharmacol 2003 Aug; 52(2): 167–74
Schroeder PE, Hofland KF, Jensen PB, et al. Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemother Pharmacol 2004 Jan; 53(1): 91–3
Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997 Apr; 15(4): 1318–32
Marty M, Espie M, Llombart A, et al. A phase III study to investigate the cardioprotective potential of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients undergoing anthracycline-based chemotherapy [abstract and poster no. 5052]. 27th Breast Cancer Symposium; 2004 Dec 8–11; San Antonio
Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992 Jan; 10(1): 117–27
Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996 Dec; 14(12): 3112–20
Vici P, Ferraironi A, Di Lauro L, et al. Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment. Clin Ter Jan–Feb 1998; 149: 15–20
Feldmann JE, Jones SE, Weisberg SR, et al. Advanced small cell lung cancer treated with CAV (cyclophosphamide + Adriamycin® + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard®) [abstract no. 993]. Proc Am Soc Clin Oncol 1992 Mar; 11: 296
Lopez M, Vici P, Di Lauro L, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998 Jan; 16(1): 86–92
Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996 Feb; 14(2): 362–72
Lipshultz SE, Rifai N, Daltaon VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004 Jul 8; 351(2): 145–53
Jelić S, Radulović S, Nešskovic-Konstantinovic Z, et al. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen. Support Care Cancer 1995; 3(3): 176–82
Chiron Corporation. Dexrazoxane: CS-CX-002 clinical study report. 2004 Jun 16. (Data on file)
Chiron Corporation Ltd. Dexrazoxane: 2.7.6 synopses of individual studies. 2003 May. (Data on file)
Chiron Corporation Ltd. Dexrazoxane: 2.7.6 synopses of individual studies. 2004 Jun 1. (Data on file)
Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997 Apr; 15(4): 1333–40
The Criteria Committee of the New York Heart Association. Functional capacity and objective assessment. In: Dolgin M, editor. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston (MA): Little, Brown and Company, 1994: 253–5
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982 Dec; 5: 649–55
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981 Jan 1; 47(1): 207–14
Lemez P, Marešová J. Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias. Neoplasma 1996; 43(6): 417–9
Lemez P, Marešová J. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy. Semin Oncol 1998 Aug; 25 (4 Suppl. 10): 61–5
Woodlock TJ, Lifton R, Disalle M. Coincident acute myelogenous leukemia and ischemic heart disease: use of the cardioprotectant dexrazoxane during induction chemotherapy. Am J Hematol 1998 Nov; 59: 246–8
Orditura M, De Rimini ML, Ciaramella F, et al. Is ICRF-187 effective against doxorubicin induced cardiotoxicity? Med Microbiol Lett 1996 May; 5 Suppl. 1: 107
Mladosievicová B, Foltinová A, Petrášová H, et al. Signal-averaged electrocardiography in survivors of Hodgkin’s disease treated with and without dexrazoxane. Neoplasma 2001; 48(1): 61–5
Schiavetti A, Castello MA, Versacci P, et al. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr Hematol Oncol 1997; 14: 213–22
Bu’Lock FA, Gabriel HM, Oakhill A, et al. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 1993; 70: 185–8
Silverman LB, Levy DE, Dalton VK, et al. Outcome of Dana-Farber Cancer Institute (DFCI) Consortium Protocol 95-01 for children with newly diagnosed acute lymphoblastic leukemia (ALL) [abstract no. 679]. Blood 2004 Nov 16; 104 (11 Pt 1): 195
van Dalen E, Caron H, Dickinson H, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005 Jan 24; (1): CD003917
Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer: the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999 Apr; 3(2): 145–59
Bates M, Lieu D, Zagari M, et al. A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV meta-static breast cancer. Clin Ther 1997; 19(1): 167–84
Tonkin K, Bates M, Lieu D, et al. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation. Can J Oncol 1996 Nov; 6(2): 458–73
Bristow MR, Lopez MB, Mason JW, et al. Cancer 1982; 50: 32–41
Baker MS, Kessler LG, Urban N, et al. Estimating the treatment costs of breast and lung cancer. Med Care 1991; 29: 40–9
Grover TS, Martin C, Gao S, et al. A cost-effectiveness analysis of the use of bolus, continuous and dexrazoxane-associated infusion of doxorubicin in breast cancer in the reduction of cardiomyopathy related morbidity and mortality [abstract no. 962]. Proc Am Soc Clin Oncol 2001 May 12; 20 (Pt 1): 241
Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002 Jun 15; 20(12): 2895–903
Chiron France. Cardioxane®: summary of product characteristics. Sureness: Chiron France, 2000 Oct 9
Chiron B.V. Cardioxane® Ireland: summary of product characteristics. Amsterdam: Chiron B.V., 2003 Jun
Chiron B.V. Summary of product characteristics for Cardioxane®, powder for solution for infusion. Amsterdam: Chiron B.V., 2004 Jan 9
Chiron B.V. Cardioxane® (dexrazoxane) summary of product characteristics/data sheet. Vienna: Chiron B.V., 2000 Jan
Chiron Italia Srl. Cardioxane® (dexrazoxane, 500mg): summary of product characteristics. Milan: Chiron Italia Srl, 2001 Feb
Pouillart P. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treat Rev 2004 Nov; 30(7): 643–50
Simpson C, Herr H, Courville KA. Concurrent therapies that protect against doxorubicin-induced cardiomyopathy. Clin J Oncol Nurs 2004 Oct; 8(5): 497–501
Schmid P, Possinger K. Liposomal anthracyclines for improved cardiac tolerability. Breast 2001; 10 Suppl. 2: 22–7
Dando TM, Keating GM. Liposomal doxorubicin: a review of its use in metastatic breast cancer. Am J Cancer. In Press
Dorr RT. Cytoprotective agents for anthracyclines. Semin Oncol 1996 Aug; 23 (4 Suppl. 8): 23–34
Myers CE, Bonow R, Palmeri S, et al. A randomised controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983 Mar; 10 (1 Suppl. 1): 53–5
Legha S, Wang YM, Mackay B, et al. Clinical and pharmacological investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann N Y Acad Sci 1982; 393: 411
VonHoff DD. Phase I trials of dexrazoxane and other potential applications for the agent. Semin Oncol 1998 Aug; 25 (4 Suppl. 10): 31–6
Elihu N, Anandasbapathy S, Frishman WH. Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane. J Clin Pharmacol 1998 Feb; 38: 101–5
Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 2000 Sep; 6: 3680–6
Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol 2001; 12: 405–10
Langer SW, Sehested M, Jensen PB, et al. Dexrazoxane in anthracycline extravasation [letter]. J Clin Oncol 2000 Aug; 18(16): 3064
Bos AM, van der Graaf WT, Willemse PH. A new conservative approach to extravasation of anthracyclines with dimethyl-sulfoxide and dexrazoxane. Acta Oncol 2001; 40(4): 541–2
Jensen JN, Lock-Andersen J, Langer SW, et al. Dexrazoxane: a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plast Reconstr Surg Hand Surg 2003; 37(3): 174–5
El-Saghir N, Otrock Z, Mufarrij A, et al. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol 2004 May; 5(5): 320–1
Holm B, Jensen PB, Sehested M. ICRF-187 rescue in etoposide treatment in vivo: a model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 1996 Jul; 38: 203–9
Holm B, Sehested M, Jensen PB, et al. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 1998 Jun; 4: 1367-73
Author information
Authors and Affiliations
Corresponding author
Additional information
Various sections of the manuscript reviewed by: M.S. Ewer, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA; S. Goodin, Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; E.H. Herman, Division of Applied Pharmacology Research, FDA, Silver Spring, Maryland, USA; S.W. Langer, Laboratory of Experimental Medical Oncology, The Finsen Center, Copenhagen University Hospital, Copenhagen, Denmark; M. Lopez, Division of Medical Oncology B, Regina Elena Institute for Cancer Research, Rome, Italy; P. Vici, Division of Medical Oncology B, Regina Elena Institute for Cancer Research, Rome, Italy.
Data Selection
Sources: Medical literature published in any language since 1980 on dexrazoxane, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.
Search strategy: MEDLINE and AdisBase search terms were ‘dexrazoxane’ or ‘ADR-529’ or ‘ICRF-187’. Searches were last updated 18 March 2005.
Selection: Studies in adult and paediatric patients with solid tumours or haematological malignancies who received intravenous dexrazoxane infusion along with an anthracycline or anthracycline-based chemotherapy. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.
Index terms: Recombinant hepatitis B vaccine, hepatitis B, immunisation, immunogenicity, protective efficacy.
Rights and permissions
About this article
Cite this article
Cvetković, R.S., Scott, L.J. Dexrazoxane. CNS Drugs 65, 1005–1024 (2005). https://doi.org/10.2165/00003495-200565070-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200565070-00008